Previous Article | Next Article ![]()
Antimicrobial Agents and Chemotherapy, March 1999, p. 530-536, Vol. 43, No. 3
New Product Research Laboratories I,
Daiichi Pharmaceutical Co., Ltd., Tokyo, Japan
Received 5 October 1998/Returned for modification 12 November
1998/Accepted 30 December 1998
The topoisomerase IV subunit A gene, parC homolog, has
been cloned and sequenced from Pseudomonas aeruginosa PAO1,
with cDNA encoding the N-terminal region of Escherichia coli
parC used as a probe. The homolog and its upstream gene were
presumed to be parC and parE through sequence
homology with the parC and parE genes of other
organisms. The deduced amino acid sequence of ParC and ParE showed 33 and 32% identity with that of the P. aeruginosa DNA gyrase
subunits, GyrA and GyrB, respectively, and 69 and 75% identity with
that of E. coli ParC and ParE, respectively. The putative
ParC and ParE proteins were overexpressed and separately purified by
use of a fusion system with a maltose-binding protein, and their
enzymatic properties were examined. The reconstituted enzyme had
ATP-dependent decatenation activity, which is the main catalytic
activity of bacterial topoisomerase IV, and relaxing activities but had
no supercoiling activity. So, the cloned genes were identified as
P. aeruginosa topoisomerase IV genes. The inhibitory effects of quinolones on the activities of topoisomerase IV and DNA
gyrase were compared. The 50% inhibitory concentrations of quinolones
for the decatenation activity of topoisomerase IV were from five to
eight times higher than those for the supercoiling activities of
P. aeruginosa DNA gyrase. These results confirmed that
topoisomerase IV is less sensitive to fluoroquinolones than is DNA
gyrase and may be a secondary target of new quinolones in wild-type
P. aeruginosa.
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Cloning, Expression, and Enzymatic
Characterization of Pseudomonas aeruginosa
Topoisomerase IV
*
Corresponding author. Mailing address: New Product
Research Laboratories I, Daiichi Pharmaceutical Co., Ltd., 16-13, Kitakasai 1-Chome, Edogawa-ku, Tokyo 134-8630, Japan. Phone:
81-3-3680-0151. Fax: 81-3-5696-8344. E-mail:
akasa94k{at}daiichipharm.co.jp.
This article has been cited by other articles:
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»